Understanding how certain signals contribute to persistent cancer cells in lung cancer models
Elucidating the role of support signaling in promoting minimal residual disease in mouse models of oncogene-driven lung cancer
This study is looking at how certain genetic changes in lung cancer can affect how well treatments work, using special models to understand why some cancer cells might survive even after therapy, which could help create better treatments for patients in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10872298 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind minimal residual disease (MRD) in lung cancer, focusing on how specific genetic mutations influence treatment responses. By using advanced mouse and organoid models, the study aims to dissect the roles of various proteins, particularly those in the EGFR family, in the development of drug resistance. Patients may benefit from insights gained into why some cancer cells survive treatment, potentially leading to more effective therapies in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients with specific oncogenic mutations who are undergoing treatment.
Not a fit: Patients with lung cancer who do not have identifiable genetic mutations or those who are not currently receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that effectively target and eliminate residual cancer cells, reducing the risk of relapse.
How similar studies have performed: Previous research has shown promising results in understanding drug resistance mechanisms in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Vaishnavi, Aria — University of Tx Md Anderson Can Ctr
- Study coordinator: Vaishnavi, Aria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.